Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 12/20 | 0.43 |
| ▸ | XIAP | P98170 | 12/20 | 0.43 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25555470 | 0.90 | RIPK2 (0.43) | RIPK2XIAPBIRC3ESR1TRPV1 | |
| SCHEMBL21350495 | 0.90 | RIPK2 (0.43) | RIPK2XIAPBIRC3ESR1TRPV1 | |
| SCHEMBL10075880 | 0.89 | RIPK2 (0.36) | RIPK2XIAPBIRC3ESR1CTSL | |
| SCHEMBL23884348 | 0.88 | RIPK2 (0.36) | RIPK2XIAPBIRC3ESR1BIRC2 | |
| SCHEMBL21472349 | 0.88 | RIPK2 (0.36) | RIPK2XIAPBIRC3ESR1BIRC2 | |
| SCHEMBL23884350 | 0.88 | RIPK2 (0.36) | RIPK2XIAPBIRC3ESR1BIRC2 | |
| SCHEMBL22835664 | 0.88 | RIPK2 (0.36) | RIPK2XIAPBIRC3ESR1BIRC2 | |
| SCHEMBL21472327 | 0.88 | RIPK2 (0.37) | RIPK2XIAPBIRC3ESR1TRPV1 | |
| SCHEMBL24926173 | 0.87 | USP30 (0.37) | RIPK2XIAPESR1 | |
| SCHEMBL29836916 | 0.87 | USP30 (0.37) | RIPK2XIAPESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081319-A1 | Solid Oral Formulations and Crystalline Forms of an Inhibitor of Apoptosis Protein | NOVARTIS AG (CH) | 2017-03-23 | — | — | US | disclosed |
| US-20170081319-A1 | Solid Oral Formulations and Crystalline Forms of an Inhibitor of Apoptosis Protein | NOVARTIS AG (CH) | 2017-03-23 | — | — | US | disclosed |
| US-9540363-B2 | Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein | NOVARTIS AG (CH) | 2017-01-10 | — | — | US | disclosed |
| US-9540363-B2 | Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein | NOVARTIS AG (CH) | 2017-01-10 | — | — | US | disclosed |
| US-8623385-B2 | Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein | NOVARTIS AG (CH) | 2014-01-07 | — | — | US | disclosed |
| US-8623385-B2 | Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein | NOVARTIS AG (CH) | 2014-01-07 | — | — | US | disclosed |
| US-20120128742-A1 | SOLID ORAL FORMULATIONS AND CRYSTALLINE FORMS OF AN INHIBITOR OF APOPTOSIS PROTEIN | NOVARTIS AG (CH) | 2012-05-24 | — | — | US | disclosed |
| US-20120128742-A1 | SOLID ORAL FORMULATIONS AND CRYSTALLINE FORMS OF AN INHIBITOR OF APOPTOSIS PROTEIN | NOVARTIS AG (CH) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081319-A1 | Solid Oral Formulations and Crystalline Forms of an Inhibitor of Apoptosis Protein | API5, BAX, BCL2 | RIPK2 599/4885XIAP 367/4885BIRC3 121/4885 |
| US-20120128742-A1 | SOLID ORAL FORMULATIONS AND CRYSTALLINE FORMS OF AN INHIBITOR OF APOPTOSIS PROTEIN | API5, BAX, BCL2 | RIPK2 623/4885XIAP 322/4885BIRC3 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.